Compass Therapeutics (CMPX) Operating Leases (2021 - 2026)
Compass Therapeutics recorded quarterly Operating Leases of $9.8 million in Q1 2026, up 10.9% quarter-over-quarter from $8.8 million in Q4 2025, and up 53.44% year-over-year from $6.4 million in Q1 2025.
Compass Therapeutics' Operating Leases history runs 6 years deep, the most recent figure standing at $9.8 million for Q1 2026.
- In Q1 2026, Operating Leases rose 53.44% year-over-year to $9.8 million; the TTM figure through Mar 2026 stood at $9.8 million (up 53.44% YoY), while the FY2025 annual figure was $8.8 million, up 40.23% from the prior year.
- Operating Leases came in at $9.8 million for Q1 2026 at Compass Therapeutics, up from $8.8 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $9.8 million in Q3 2025 to a low of $189000.0 in Q1 2024.
- A 5-year average of $4.4 million and a median of $3.2 million in 2022 frame the typical range for Operating Leases.
- Across the five-year window, Operating Leases tumbled 92.85% in 2024 and jumped 3276.19% in 2025, its largest moves.
- Compass Therapeutics' Operating Leases stood at $1.8 million in 2022, then plunged by 70.84% to $536000.0 in 2023, then surged by 1074.63% to $6.3 million in 2024, then soared by 40.23% to $8.8 million in 2025, then advanced by 10.9% to $9.8 million in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $9.8 million, $8.8 million, and $9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Compass Therapeutics | 418.47 Mn | 223.78 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 9.79 Mn |
| Dec 31, 2025 | 8.83 Mn |
| Sep 30, 2025 | 9.83 Mn |
| Jun 30, 2025 | 9.63 Mn |
| Mar 31, 2025 | 6.38 Mn |
| Dec 31, 2024 | 6.30 Mn |
| Sep 30, 2024 | 6.88 Mn |
| Jun 30, 2024 | 1.09 Mn |
| Mar 31, 2024 | 189,000.00 |
| Dec 31, 2023 | 536,000.00 |
| Sep 30, 2023 | 869,000.00 |
| Jun 30, 2023 | 1.20 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 1.84 Mn |
| Sep 30, 2022 | 3.22 Mn |
| Jun 30, 2022 | 3.50 Mn |
| Mar 31, 2022 | 2.74 Mn |
| Dec 31, 2021 | 3.05 Mn |
| Sep 30, 2021 | 3.33 Mn |
| Mar 31, 2021 | 3.88 Mn |